Generic Name: cabotegravir
Abbreviation: CAB LA
Drug Class: Integrase Inhibitors
Company: ViiV Healthcare
Approval Status: Experimental
Generic Version Available: No
Cabotegravir has not yet been reviewed for inclusion in the DHHS list of recommended medications for HIV treatment or prevention.
Cabotegravir is an experimental long-acting injectable HIV medication. It contains one integrase inhibitor. It is currently in Phase III clinical trials for the prevention of HIV as pre-exposure prophylaxis (PrEP).
This is a long-acting injectable HIV medication administered every eight weeks.
Last Reviewed: September 25, 2018